Variant antibodies that bind aip2
AssigneeSorrento Therapeutics, Inc.
InventorsYanliang Zhang, Gunnar F. Kaufmann
Life of this patent
Estimating the term…
Abstract
The present disclosure provides fully human variant anti-AIP2 variant antibodies, and antigen binding proteins thereof, having improved characteristics compared to the wild type anti-AIP2 antibody E7 from which the variant clones are derived. The variant anti-AIP2 antibodies exhibit improved binding to AIP1 and AIP4 as determined in an in vitro quorum sensing reporter assay, have improved thermal stability, provided complete protection against infection with two different strains of Staphylococcus aureus MRSA in pre-treated mice, and can be manufactured at higher yields.
Claims24
A fully human antibody that binds to Staphylococcus aureus autoinducing peptide-2 (AIP2), wherein the antibody comprises heavy chain/light chain variable domain amino acid sequences selected from the group consisting of
- SEQ ID NO:4 for heavy chain/SEQ ID NO:2 for the light chain for 2A7,
- SEQ ID NO:
- 3 for heavy chain/SEQ ID NO:
- 2 for the light chain for 1G3,
- SEQ ID NO:5 for heavy chain/SEQ ID NO:2 for the light chain for 2B12,
- SEQ ID NO:6 for heavy chain/SEQ ID NO:2 for the light chain for 2(E)6,
- SEQ ID NO:7 for heavy chain/SEQ ID NO:2 for the light chain for 2H5,
- SEQ ID NO:8 for heavy chain/SEQ ID NO:9 for the light chain for X18,
- SEQ ID NO:10 for heavy chain/SEQ ID NO:11 for the light chain for X12, and
- SEQ ID NO:
- 12 for heavy chain/SEQ ID NO:9 for the light chain for 2H5V.
Dependencies are inferred from the claim text.